{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T14:10:42Z","timestamp":1775571042331,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,7]]},"DOI":"10.7759\/cureus.106584","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T13:23:16Z","timestamp":1775568196000},"source":"Crossref","is-referenced-by-count":0,"title":["Janus Kinase and Interleukin-6 Inhibitor-Induced Lipid Modulation and Its Association With Major Adverse Cardiovascular Events in Rheumatoid Arthritis: A Systematic Review of Clinical and Biomarker Evidence"],"prefix":"10.7759","author":[{"given":"Rohan M","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lila","family":"Dudley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mackenzie","family":"Morse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos G","family":"Mihos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc M","family":"Kesselman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Rheumatoid arthritis","author":"Chauhan K","year":"2026","unstructured":"Chauhan K, Jandu JS, Brent LH, et al.. Rheumatoid arthritis. StatPearls [Internet]. StatPearls Publishing,  Treasure Island (FL); 2026."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0720-048X(98)00038-2","article-title":"The clinical features of rheumatoid arthritis","volume":"27","author":"Grassi W","year":"1998","unstructured":"Grassi W, De Angelis R, Lamanna G, Cervini C. The clinical features of rheumatoid arthritis. Eur J Radiol. 1998, 27:S18-S24. 10.1016\/S0720-048X(98)00038-2","journal-title":"Eur J Radiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2018.07.004","article-title":"Methotrexate mechanism in treatment of rheumatoid arthritis","volume":"86","author":"Friedman B","year":"2019","unstructured":"Friedman B, Cronstein B. Methotrexate mechanism in treatment of rheumatoid arthritis. Joint Bone Spine. 2019, 86:301-307. 10.1016\/j.jbspin.2018.07.004","journal-title":"Joint Bone Spine"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen JS","year":"2020","unstructured":"Smolen JS, Landewe RBM, Bijlsma JWJ, et al.. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheu Dis. 2020, 79:685-699. 10.1136\/annrheumdis-2019-216655","journal-title":"Ann Rheu Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2013.07.010","article-title":"Rheumatoid arthritis and cardiovascular disease","volume":"166","author":"Crowson CS","year":"2013","unstructured":"Crowson CS, Liao KP, Davis JM 3rd, et al.. Rheumatoid arthritis and cardiovascular disease. Am Heart J. 2013, 166:622-628.e1. 10.1016\/j.ahj.2013.07.010","journal-title":"Am Heart J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26073071","article-title":"Chronic inflammatory diseases and cardiovascular risk: current insights and future strategies for optimal management","volume":"26","author":"Cacciatore S","year":"2025","unstructured":"Cacciatore S, Andaloro S, Bernardi M, et al.. Chronic inflammatory diseases and cardiovascular risk: current insights and future strategies for optimal management. Int J Mol Sci. 2025, 26:3071. 10.3390\/ijms26073071","journal-title":"Int J Mol Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/01.bor.0000218951.65601.bf","article-title":"Cardiovascular disease in rheumatoid arthritis","volume":"18","author":"Kaplan MJ","year":"2006","unstructured":"Kaplan MJ. Cardiovascular disease in rheumatoid arthritis. Curr Opin Rheumatol. 2006, 18:289-297. 10.1097\/01.bor.0000218951.65601.bf","journal-title":"Curr Opin Rheumatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.15420\/ecr.2020.44","article-title":"Atherosclerotic cardiovascular disease in rheumatoid arthritis: impact of inflammation and antirheumatic treatment","volume":"16","author":"Kerola AM","year":"2021","unstructured":"Kerola AM, Rollefstad S, Semb AG. Atherosclerotic cardiovascular disease in rheumatoid arthritis: impact of inflammation and antirheumatic treatment. Eur Cardiol. 2021, 16:e18. 10.15420\/ecr.2020.44","journal-title":"Eur Cardiol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21249505","article-title":"The lipid paradox as a metabolic checkpoint and its therapeutic significance in ameliorating the associated cardiovascular risks in rheumatoid arthritis patients","volume":"21","author":"Behl T","year":"2020","unstructured":"Behl T, Kaur I, Sehgal A, et al.. The lipid paradox as a metabolic checkpoint and its therapeutic significance in ameliorating the associated cardiovascular risks in rheumatoid arthritis patients. Int J Mol Sci. 2020, 21:9505. 10.3390\/ijms21249505","journal-title":"Int J Mol Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21197390","article-title":"Clinical aspects of Janus Kinase (JAK) inhibitors in the cardiovascular system in patients with rheumatoid arthritis","volume":"21","author":"Kotyla PJ","year":"2020","unstructured":"Kotyla PJ, Islam MA, Engelmann M. Clinical aspects of Janus Kinase (JAK) inhibitors in the cardiovascular system in patients with rheumatoid arthritis. Int J Mol Sci. 2020, 21:7390. 10.3390\/ijms21197390","journal-title":"Int J Mol Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222259","article-title":"Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance","volume":"82","author":"Charles-Schoeman C","year":"2023","unstructured":"Charles-Schoeman C, Buch MH, Dougados M, et al.. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Ann Rheum Dis. 2023, 82:119-129. 10.1136\/ard-2022-222259","journal-title":"Ann Rheum Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222543","article-title":"Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial","volume":"82","author":"Curtis JR","year":"2023","unstructured":"Curtis JR, Yamaoka K, Chen YH, et al.. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2023, 82:331-343. 10.1136\/ard-2022-222543","journal-title":"Ann Rheum Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14051001","article-title":"A comprehensive overview of globally approved JAK inhibitors","volume":"14","author":"Shawky AM","year":"2022","unstructured":"Shawky AM, Almalki FA, Abdalla AN, Abdelazeem AH, Gouda AM. A comprehensive overview of globally approved JAK inhibitors. Pharmaceutics. 2022, 14:1001. 10.3390\/pharmaceutics14051001","journal-title":"Pharmaceutics"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18122563","article-title":"Cellular and oxidative mechanisms associated with interleukin-6 signaling in the vasculature","volume":"18","author":"Didion SP","year":"2017","unstructured":"Didion SP. Cellular and oxidative mechanisms associated with interleukin-6 signaling in the vasculature. Int J Mol Sci. 2017, 18:2563. 10.3390\/ijms18122563","journal-title":"Int J Mol Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2147\/tcrm.s3470","article-title":"Interleukin-6 inhibitors in the treatment of rheumatoid arthritis","volume":"4","author":"Hennigan S","year":"2008","unstructured":"Hennigan S, Kavanaugh A. Interleukin-6 inhibitors in the treatment of rheumatoid arthritis. Ther Clin Risk Manag. 2008, 4:767-775. 10.2147\/tcrm.s3470","journal-title":"Ther Clin Risk Manag"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-024-01259-7","article-title":"IL-6 and cardiovascular risk: a narrative review","volume":"27","author":"Mehta NN","year":"2024","unstructured":"Mehta NN, deGoma E, Shapiro MD. IL-6 and cardiovascular risk: a narrative review. Curr Atheroscler Rep. 2024, 27:12. 10.1007\/s11883-024-01259-7","journal-title":"Curr Atheroscler Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2021.155742","article-title":"Systemic effects of IL-6 blockade in rheumatoid arthritis beyond the joints","volume":"149","author":"Jarlborg M","year":"2022","unstructured":"Jarlborg M, Gabay C. Systemic effects of IL-6 blockade in rheumatoid arthritis beyond the joints. Cytokine. 2022, 149:155742. 10.1016\/j.cyto.2021.155742","journal-title":"Cytokine"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/ehjqcco\/qcae008","article-title":"Defining the need for cardiovascular event definitions","volume":"10","author":"Bhatty A","year":"2024","unstructured":"Bhatty A, Wilkinson C, Sydes M, Gale CP. Defining the need for cardiovascular event definitions. Eur Heart J Qual Care Clin Outcomes. 2024, 10:105-107. 10.1093\/ehjqcco\/qcae008","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001465","article-title":"Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE)","volume":"7","author":"Aletaha D","year":"2021","unstructured":"Aletaha D, Bingham CO, Karpouzas GA, et al.. Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE). RMD Open. 2021, 7:e001465. 10.1136\/rmdopen-2020-001465","journal-title":"RMD Open"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5535486","article-title":"Tocilizumab effect on lipid profile in correlation to cardiovascular events: a retrospective cohort study","volume":"2021","author":"Alsulaim T","year":"2021","unstructured":"Alsulaim T, Alhassan N, Khalil H, Almutlaq A. Tocilizumab effect on lipid profile in correlation to cardiovascular events: a retrospective cohort study. Int J Rheumatol. 2021, 2021:5535486. 10.1155\/2021\/5535486","journal-title":"Int J Rheumatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14080834","article-title":"Non-invasive assessment of micro- and macrovascular function after initiation of JAK inhibitors in patients with rheumatoid arthritis","volume":"14","author":"Anyfanti P","year":"2024","unstructured":"Anyfanti P, Angeloudi E, Dara A, et al.. Non-invasive assessment of micro- and macrovascular function after initiation of JAK inhibitors in patients with rheumatoid arthritis. Diagnostics (Basel). 2024, 14:834. 10.3390\/diagnostics14080834","journal-title":"Diagnostics (Basel)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13091303","article-title":"ReLiFiRa (Real Life Filgotinib in Rheumatoid Arthritis): retrospective study of efficacy and safety in common clinical practice","volume":"13","author":"Benucci M","year":"2023","unstructured":"Benucci M, Bardelli M, Cazzato M, et al.. ReLiFiRa (Real Life Filgotinib in Rheumatoid Arthritis): retrospective study of efficacy and safety in common clinical practice. J Pers Med. 2023, 13:1303. 10.3390\/jpm13091303","journal-title":"J Pers Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003392","article-title":"MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis","volume":"9","author":"Charles-Schoeman C","year":"2023","unstructured":"Charles-Schoeman C, Choy E, McInnes IB, et al.. MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. RMD Open. 2023, 9:e003392. 10.1136\/rmdopen-2023-003392","journal-title":"RMD Open"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/art.40911","article-title":"Risk factors for major adverse cardiovascular events in phase III and long-term extension studies of tofacitinib in patients with rheumatoid arthritis","volume":"71","author":"Charles-Schoeman C","year":"2019","unstructured":"Charles-Schoeman C, DeMasi R, Valdez H, et al.. Risk factors for major adverse cardiovascular events in phase III and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol. 2019, 71:1450-1459. 10.1002\/art.40911","journal-title":"Arthritis Rheumatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.05.014","article-title":"Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor","volume":"46","author":"Charles-Schoeman C","year":"2016","unstructured":"Charles-Schoeman C, Wicker P, Gonzalez-Gay MA, et al.. Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor. Semin Arthritis Rheum. 2016, 46:261-271. 10.1016\/j.semarthrit.2016.05.014","journal-title":"Semin Arthritis Rheum"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218510","article-title":"Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme","volume":"80","author":"Cohen SB","year":"2021","unstructured":"Cohen SB, van Vollenhoven RF, Winthrop KL, et al.. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis. 2021, 80:304-311. 10.1136\/annrheumdis-2020-218510","journal-title":"Ann Rheum Dis"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3390\/biom12101483","article-title":"Effects of one-year tofacitinib therapy on lipids and adipokines in association with vascular pathophysiology in rheumatoid arthritis","volume":"12","author":"Cz\u00f3kolyov\u00e1 M","year":"2022","unstructured":"Cz\u00f3kolyov\u00e1 M, Hamar A, Pusztai A, et al.. Effects of one-year tofacitinib therapy on lipids and adipokines in association with vascular pathophysiology in rheumatoid arthritis. Biomolecules. 2022, 12:1483. 10.3390\/biom12101483","journal-title":"Biomolecules"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210094","article-title":"Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study","volume":"76","author":"Dougados M","year":"2017","unstructured":"Dougados M, van der Heijde D, Chen YC, et al.. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis. 2017, 76:88-95. 10.1136\/annrheumdis-2016-210094","journal-title":"Ann Rheum Dis"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-024-01325-z","article-title":"Impact of age and cardiovascular risk factors on the incidence of adverse events in patients with rheumatoid arthritis treated with Janus Kinase inhibitors: data from a real-life multicentric cohort","volume":"24","author":"Gentileschi S","year":"2024","unstructured":"Gentileschi S, Gaggiano C, Damiani A, et al.. Impact of age and cardiovascular risk factors on the incidence of adverse events in patients with rheumatoid arthritis treated with Janus Kinase inhibitors: data from a real-life multicentric cohort. Clin Exp Med. 2024, 24:62. 10.1007\/s10238-024-01325-z","journal-title":"Clin Exp Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252212425","article-title":"Interleukin-6: cardiovascular aspects of long-term cytokine suppression in patients with rheumatoid arthritis","volume":"25","author":"Gerasimova EV","year":"2024","unstructured":"Gerasimova EV, Popkova TV, Kirillova IG, Gerasimova DA, Nasonov EL, Lila AM. Interleukin-6: cardiovascular aspects of long-term cytokine suppression in patients with rheumatoid arthritis. Int J Mol Sci. 2024, 25:12425. 10.3390\/ijms252212425","journal-title":"Int J Mol Sci"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223050","article-title":"Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis","volume":"82","author":"Molander V","year":"2023","unstructured":"Molander V, Bower H, Frisell T, Delcoigne B, Di Giuseppe D, Askling J. Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis. Ann Rheum Dis. 2023, 82:189-197. 10.1136\/ard-2022-223050","journal-title":"Ann Rheum Dis"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-019-04303-x","article-title":"Dynamics of body mass index and visceral adiposity index in patients with rheumatoid arthritis treated with tofacitinib","volume":"39","author":"Novikova DS","year":"2019","unstructured":"Novikova DS, Udachkina HV, Markelova EI, Kirillova IG, Misiyuk AS, Demidova NV, Popkova TV. Dynamics of body mass index and visceral adiposity index in patients with rheumatoid arthritis treated with tofacitinib. Rheumatol Int. 2019, 39:1181-1189. 10.1007\/s00296-019-04303-x","journal-title":"Rheumatol Int"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-021-00304-0","article-title":"Effect of tocilizumab on LDL and HDL characteristics in patients with rheumatoid arthritis. An observational study","volume":"8","author":"Pierini FS","year":"2021","unstructured":"Pierini FS, Botta E, Soriano ER, et al.. Effect of tocilizumab on LDL and HDL characteristics in patients with rheumatoid arthritis. An observational study. Rheumatol Ther. 2021, 8:803-815. 10.1007\/s40744-021-00304-0","journal-title":"Rheumatol Ther"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1002\/art.38920","article-title":"An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy","volume":"67","author":"Rao VU","year":"2015","unstructured":"Rao VU, Pavlov A, Klearman M, et al.. An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy. Arthritis Rheumatol. 2015, 67:372-380. 10.1002\/art.38920","journal-title":"Arthritis Rheumatol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30419-2","article-title":"Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study","volume":"393","author":"Smolen JS","year":"2019","unstructured":"Smolen JS, Pangan AL, Emery P, et al.. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019, 393:2303-2311. 10.1016\/S0140-6736(19)30419-2","journal-title":"Lancet"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1002\/art.40841","article-title":"Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis","volume":"71","author":"Taylor PC","year":"2019","unstructured":"Taylor PC, Weinblatt ME, Burmester GR, et al.. Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis. Arthritis Rheumatol. 2019, 71:1042-1055. 10.1002\/art.40841","journal-title":"Arthritis Rheumatol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1267749","article-title":"Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study","volume":"14","author":"Yoshida S","year":"2023","unstructured":"Yoshida S, Miyata M, Suzuki E, et al.. Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study. Front Immunol. 2023, 14:1267749. 10.3389\/fimmu.2023.1267749","journal-title":"Front Immunol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JAC","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3390\/publications14010004","article-title":"The Newcastle-Ottawa scale for assessing the quality of studies in systematic reviews","volume":"14","author":"Gualdi-Russo E","year":"2026","unstructured":"Gualdi-Russo E, Zaccagni L. The Newcastle-Ottawa scale for assessing the quality of studies in systematic reviews. Publications. 2026, 14:4. 10.3390\/publications14010004","journal-title":"Publications"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1093\/jalm\/jfac069","article-title":"Comparison of high-sensitivity C-reactive protein vs C-reactive protein for cardiovascular risk prediction in chronic cardiac disease","volume":"7","author":"Han E","year":"2022","unstructured":"Han E, Fritzer-Szekeres M, Szekeres T, Gehrig T, Gy\u00f6ngy\u00f6si M, Bergler-Klein J. Comparison of high-sensitivity C-reactive protein vs C-reactive protein for cardiovascular risk prediction in chronic cardiac disease. J Appl Lab Med. 2022, 7:1259-1271. 10.1093\/jalm\/jfac069","journal-title":"J Appl Lab Med"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.135871","article-title":"Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease","volume":"70","author":"Myasoedova E","year":"2011","unstructured":"Myasoedova E, Crowson CS, Kremers HM, Roger VL, Fitz-Gibbon PD, Therneau TM, Gabriel SE. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011, 70:482-487. 10.1136\/ard.2010.135871","journal-title":"Ann Rheum Dis"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu224","article-title":"Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment","volume":"53","author":"Choy E","year":"2014","unstructured":"Choy E, Ganeshalingam K, Semb AG, Szekanecz Z, Nurmohamed M. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology (Oxford). 2014, 53:2143-2154. 10.1093\/rheumatology\/keu224","journal-title":"Rheumatology (Oxford)"},{"key":"ref44","article-title":"Physiology, acute phase reactants","author":"Gulhar R","year":"2023","unstructured":"Gulhar R, Ashraf MA, Jialal I. Physiology, acute phase reactants. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key302","article-title":"Lipid screening and statins alongside disease-modifying anti-rheumatic drugs for patients with rheumatoid arthritis","volume":"58","author":"Navarro-Mill\u00e1n I","year":"2019","unstructured":"Navarro-Mill\u00e1n I, Goyal P, Safford MM. Lipid screening and statins alongside disease-modifying anti-rheumatic drugs for patients with rheumatoid arthritis. Rheumatology (Oxford). 2019, 58:933-934. 10.1093\/rheumatology\/key302","journal-title":"Rheumatology (Oxford)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/465644-janus-kinase-and-interleukin-6-inhibitor-induced-lipid-modulation-and-its-association-with-major-adverse-cardiovascular-events-in-rheumatoid-arthritis-a-systematic-review-of-clinical-and-biomarker-evidence","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T13:23:18Z","timestamp":1775568198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/465644-janus-kinase-and-interleukin-6-inhibitor-induced-lipid-modulation-and-its-association-with-major-adverse-cardiovascular-events-in-rheumatoid-arthritis-a-systematic-review-of-clinical-and-biomarker-evidence"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":45,"URL":"https:\/\/doi.org\/10.7759\/cureus.106584","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,7]]}}}